Structure Therapeutics develops oral small molecule drugs that target G protein coupled receptors to treat chronic diseases, mainly obesity. GPCR reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 3 dark pool prints.
Prices, price targets and earnings estimates for GPCR are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GPCR is in one of them and how their past GPCR trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Structure Therapeutics
Structure Therapeutics is a biopharmaceutical company based in South San Francisco, California. It is developing oral small molecule drugs that act on G protein coupled receptors, a family of receptors that control many body processes. Its most advanced candidate is aimed at obesity, and its pipeline includes other candidates for metabolic and related conditions. The company is still in clinical development, and its medicines are intended for patients with chronic diseases.
